Literature DB >> 26873795

Is low-molecular weight iron dextran really the most risky iron?--Unconvincing data from an unconvincing study.

Thomas G DeLoughery1,2, Michael Auerbach3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26873795     DOI： 10.1002/ajh.24326

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

Review 1.  Single-dose intravenous iron for iron deficiency: a new paradigm.

Authors:  Michael Auerbach; Thomas Deloughery
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents.

Authors:  Su Young Kim; Sejin An; Dong Kyun Park; Kwang An Kwon; Kyoung Oh Kim; Jun-Won Chung; Jung Ho Kim; Yoon Jae Kim
Journal:  Therap Adv Gastroenterol       Date:  2020-09-23       Impact factor: 4.409

Review 3.  Current misconceptions in diagnosis and management of iron deficiency.

Authors:  Manuel Muñoz; Susana Gómez-Ramírez; Martin Besser; José Pavía; Fernando Gomollón; Giancarlo M Liumbruno; Sunil Bhandari; Mercé Cladellas; Aryeh Shander; Michael Auerbach
Journal:  Blood Transfus       Date:  2017-09       Impact factor: 3.443

Review 4.  Safety of intravenous iron use in chronic kidney disease.

Authors:  Philip A Kalra; Sunil Bhandari
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-11       Impact factor: 2.894

5.  Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System.

Authors:  Henry Trumbo; Karolina Kaluza; Syed Numan; Lawrence T Goodnough
Journal:  Drug Saf       Date:  2020-11-25       Impact factor: 5.606
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.